Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents

@article{Griebel2005EffectsOT,
  title={Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents},
  author={Guy Griebel and Jeanne Stemmelin and Bernard Scatton},
  journal={Biological Psychiatry},
  year={2005},
  volume={57},
  pages={261-267}
}

Figures and Tables from this paper

Influence of the CB1 and CB2 cannabinoid receptor ligands on the activity of atypical antidepressant drugs in the behavioural tests in mice

Antiaversive Effects of Cannabinoids: Is the Periaqueductal Gray Involved?

The responses to intra-PAG injection of CB1 agonists in rats submitted to the elevated plus-maze, the Vogel punished licking test, or contextual aversive conditioning model suggest that the PAG could be an important site for the antiaversive effects of cannabinoids.

Anxiogenic profile of AM-251, a selective cannabinoid CB1 receptor antagonist, in plus-maze-naïve and plus-maze-experienced mice

It is confirmed that prior maze experience per se significantly increases behavioural indices of anxiety without altering measures of general activity, and the pattern of behavioural change in maze-experienced mice would also be consistent with an anxiogenic-like action of AM-251.

Interactions between environmental aversiveness and the anxiolytic effects of enhanced cannabinoid signaling by FAAH inhibition in rats

Findings show that FAAH inhibition does not affect anxiety under mildly stressful circumstances but protects against the anxiogenic effects of aversive stimuli.
...

References

SHOWING 1-10 OF 44 REFERENCES

Involvement of CB1 cannabinoid receptors in emotional behaviour

Findings demonstrate that endogenous cannabinoids through the activation of CB1 receptors are implicated in the control of emotional behaviour and participate in the physiological processes of learning and memory.

Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters

Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety‐like responses in the rat

Results demonstrate that blockade of the endogenous cannabinoid tone might induce anxiety-like responses in rats, and acute administration of SR 141716A induced defensive responses in both anxiety tests.

‘One‐trial sensitization’ to the anxiolytic‐like effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus‐maze

The apparent experientially induced ‘sensitization’ to the anxiolytic‐like effects of SR141716A in the plus‐maze contrasts markedly with the widely reported loss of benzodiazepine efficacy in test‐experienced animals.

The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety

Findings suggest that the discrepancy between the effects of the genetic and pharmacological blockade of the CB1 receptor suggests that the novel receptor plays a role in anxiety, as the cannabinoid receptor antagonist affected anxiety in both wild type and CB1‐knockout mice.

SR141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats

Results suggest that activation of the endogenous cannabinoid system may participate in the motivational and dopamine-releasing effects of nicotine and ethanol, and may be effective in reduction of alcohol consumption, as previously suggested, and as an aid for smoking cessation.

The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions

The results suggest that the cortical selectivity in the release of catecholamines, dopamine in particular, induced by the cannabinoid antagonist SR141716A, its procholinergic properties, together with its mild stimulatory effects on serotonin and norepinephrine efflux make similar compounds unique candidates for the treatment of psychosis, affective and cognitive disorders.

Behavioral effects of cannabinoid agents in animals.

In animals, cannabinoid agonists such as delta9-THC, WIN 55,212-2, and CP 55,940 produce a characteristic combination of four symptoms, hypothermia, analgesia, hypoactivity, and catalepsy, providing good evidence for the involvement of CB1-related mechanisms.

Differential effects of chronic treatment with either dopamine D1 or D2 receptor agonists on the acute neuroendocrine actions of the highly potent synthetic cannabinoid HU-210 in male rats.

This work has studied the role of hypothalamic dopaminergic receptors in the mediation of the acute neuroendocrine effects of (-)-delta 8-tetrahydrocannabinol-dimethyl-heptyl (HU-210, 20 micrograms/kg), a highly potent agonist of CB-1.